| Document |
Document Title |
|
WO/2021/068910A1 |
Disclosed are a target for screening an anti-tumor drug, the use thereof and a screening method therefor. Disclosed are an effect target for screening a drug for treating and/or preventing tumors, the effect target for screening a drug f...
|
|
WO/2021/072269A1 |
The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can b...
|
|
WO/2021/068938A1 |
Provided is a T cell receptor (TCR) capable of specifically binding to KRAS G12V mutant antigens; the mutant antigen short peptide VVGAVGVGK is capable of forming a complex with HLA A1101, and the TCR specifically binds to said complex. ...
|
|
WO/2021/072197A1 |
The invention described herein provide a modified VP1 capsid enabling preferential targeted expression of gene of interest (GOI) in muscle tissues, as well as recombinant adeno- associated virus (rAAV) with the GOI packaged with the modi...
|
|
WO/2021/069806A1 |
The present invention provides an oncolytic adenoviral vector comprising a nucleic acid sequence encoding a variant interleukin 2 (vIL-2) polypeptide as a transgene. The present invention also provides a pharmaceutical composition compri...
|
|
WO/2020/187340A3 |
The present invention describes a method for obtaining T lymphocytes and NK cells with the desired phenotype in adoptive cell transfer for cancer therapy. In particular, it is based on strategies for inducing preferential signalling usin...
|
|
WO/2021/072127A2 |
Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; sele...
|
|
WO/2021/072218A1 |
Methods of treating cancer in Non-Responder Patients with an engineered NeoTCR Product are described herein.
|
|
WO/2021/069692A1 |
The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b)...
|
|
WO/2021/072298A1 |
The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen...
|
|
WO/2021/068080A1 |
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...
|
|
WO/2021/068074A1 |
Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating f...
|
|
WO/2021/070107A1 |
The present invention relates to methods of increasing the cellular concentration of Interferon Induced Protein with Tetratricopeptide repeats (IFIT) polypeptides in a cell infected with a mycobacterium. The method includes the introduct...
|
|
WO/2021/072312A1 |
The present invention includes compositions and methods for treating AML utilizing bispecific CARs. In certain aspects, the invention includes a bispecific split CAR which binds CD13 and TIM-3 on AML cells. In one aspect, the invention p...
|
|
WO/2021/068403A1 |
Provided are active peptides for promoting osteoblast proliferation, and a use thereof. The amino acid sequences of the active peptides are as shown in SEQ ID NO: 1 to SEQ ID NO: 5. The active peptides can promote osteoblast proliferatio...
|
|
WO/2020/163300A9 |
The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a ceroid lipofuscinosis neuronal 3 (CLN3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for CLN3 gene therapy of the neu...
|
|
WO/2021/072194A1 |
The present disclosure provides stabilized hemoglobin compositions, uses thereof, and devices for administration thereof. The stabilized hemoglobin compositions may be useful in the treatment of various anemic or traumatic conditions inv...
|
|
WO/2021/072284A2 |
This document provides methods and materials related to CDV H and/or CDV F polypeptides. For example, CDV H polypeptides, CDV F polypeptides, recombinant viruses (e.g., vesicular stomatitis viruses (VSVs)) containing CDV H polypeptides a...
|
|
WO/2021/072225A1 |
Methods of modulating IL-10 signaling in a diabetic patient are provided. The methods include administering a therapeutically effective amount of an agent that inhibits Interleukin-10 (IL-10) signaling to a wound site. The agent may anta...
|
|
WO/2021/068884A1 |
Provided is a polypeptide derivative having a sequence of X-Phe-Phe-Gly-Ser-Ser-Ser-Arg, wherein the end group X is Nap or Npx, The Phes are in L configuration or D configuration simultaneously, and the rest are in L configuration, the p...
|
|
WO/2021/069915A1 |
The present invention relates to an engineered immune cell which comprises: (i) a target binding polypeptide comprising a target-binding domain and a first protein interaction domain, and (ii) a localising polypeptide comprising a second...
|
|
WO/2021/068752A1 |
Provided are a fusion protein and the medical use thereof. The fusion protein is prepared by fusing a human interleukin-10 (IL-10) with an Fc fragment of an immunoglobulin IgG via a linker peptide. The Fc fragment is the Fc fragment of h...
|
|
WO/2021/071468A1 |
Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
|
|
WO/2021/068962A1 |
Disclosed are a polypeptide for preventing, inhibiting and/or treating diseases related to angiogenesis/lymphangiogenesis and vascular endothelial dysfunction, especially cancers, ophthalmic diseases, arteriosclerosis, cardio-cerebrovasc...
|
|
WO/2021/072163A1 |
Provided herein are compositions and methods for reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to compositions and methods for transdifferentiating an age-restricted non-neuronal cell into a neur...
|
|
WO/2021/069684A1 |
The present invention is in the field of molecular biology and relates to improved methods for plant transformation and to polynucleotides and polypeptides for achieving the same.
|
|
WO/2021/072372A1 |
Provided herein are novel IGF2 peptides, fusion proteins, and nucleic acid sequences encoding novel IGF2 peptides and fusion proteins for the treatment of lysorsomal storage disorders, wherein the IGF2 peptides confer enhanced properties...
|
|
WO/2021/068040A1 |
Disclosed are antigen-binding molecules and chimeric antigen receptors (CARs) that can at least specifically recognize or bind to EphA3. Also disclosed are methods of medical treatment and prophylaxis.
|
|
WO/2021/072196A1 |
Compositions, methods, and kits are provided for assaying calpain-5 activity and inhibition. In particular, novel peptide substrates are provided for detecting calpain-5, measuring calpain-5 activity, and screening for inhibitors of calp...
|
|
WO/2021/071419A1 |
The invention relates to a Vibrio cholerae MakA (motility associated killing factor A) protein for use in therapy, in particular in the treatment or alleviation of cancer such as colorectal cancer. The invention further relates to pharma...
|
|
WO/2021/072005A1 |
The present invention provides synthetic peptides comprising an amino acid sequence of any one of SEQ ID NOs: 1-17 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to the amino acid sequence of any one of...
|
|
WO/2021/068039A1 |
The present invention relates to methods and means for producing nitrogenase polypeptides in the mitochondria of plant cells.
|
|
WO/2021/068068A1 |
Described herein are chimeric receptors comprising G-CSFR extracellular domains and the intracellular domains of various multi-subunit cytokine receptors for selective activation of cytokine signaling in cells of interest. In certain asp...
|
|
WO/2021/050792A3 |
Disclosed herein are novel glycosylated peptide receptive MHC-I complexes that allow for efficient production of glycosylated MHC-I multimers. Such glycosylated peptide receptive MHC-I complexes include a single-chain MHC-I construct and...
|
|
WO/2021/069740A1 |
The invention relates to the field of radiation oncology. The method according to the invention comprises the use of botulinum toxin and an anticholinergic agent to prevent glands from radiation damage and side-effects due to radioligand...
|
|
WO/2021/071962A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome...
|
|
WO/2021/068072A1 |
Disclosed herein is a targeted tumour-infiltrating bacteriophage. The bacteriophage is engineered to present an epidermal growth factor receptor (EGFR)-binding moiety on the bacteriophage cell surface. The EGFR-binding moiety is capable ...
|
|
WO/2021/069672A1 |
The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the develo...
|
|
WO/2021/034958A3 |
The present disclosure provides devices comprising a therapeutic agent bound to a printed three-dimensional structure. The printed three-dimensional structure comprises about 50% to about 100% by weight ceramic and about 0% to about 50% ...
|
|
WO/2021/070202A1 |
The present invention relates to improved process for manufacturing of glucagon-like peptide-1 (GLP-I) and analogs by utilizing Fmoc protected amino acids and synthesizing peptide by solid phase method. The present invention relates to i...
|
|
WO/2021/068251A1 |
A GIP and GLP-1 dual agonist polypeptide compound, related to the technical field of polypeptide medicinal chemistry. The amino acid sequence of the GIP and GLP-1 dual agonist polypeptide compound is: YXaa1EGTFTSDYSIXaa2LDKIAQXaa3AFVQWLI...
|
|
WO/2021/072075A1 |
Disclosed herein is a protein fusion technology that allows the combination of one or more cancer vaccine epitopes with scaffold domains. Also disclosed herein are polypeptide and polynucleic acid compositions encompassed by the protein ...
|
|
WO/2021/069766A1 |
The present invention relates to a polypeptide comprising an amino acid sequence according to SEQ ID NO. 3 or SEQ ID NO. 4; to the nucleotide sequences that encode the polypeptide of the invention; and to the polypeptide of the invention...
|
|
WO/2021/072056A1 |
Provided herein are compositions and methods for causing senolysis and/or treating age-related diseases through administration of a FOXO4:p53 disrupter peptide and/or a variant thereof, a cell permeable FOXO4:p53 disrupter peptide, and/o...
|
|
WO/2021/068986A1 |
Provided in the present invention is a use of novel GLP-1 fatty acid-modified or non-modified dimers of different configurations for a pancreas protecting or glucose reducing effect in treating type 2 diabetes. The dimers of the present ...
|
|
WO/2021/067290A1 |
The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the glycosyl-phosphatidylinositol (GPI)-linked GDNF family protein α-receptor 4 (GFRα4).
|
|
WO/2021/041278A3 |
Described herein are compositions and methods relating to insecticides. In additional embodiments according to the present disclosure, administration devices and methods of such are also described. In certain aspects, compositions and me...
|
|
WO/2021/067641A1 |
Compositions, kits, and methods for preparing nutrient compositions are provided. A nutrient composition can be a food composition such as a dairy composition. A nutrient composition may be produced by an engineered cell composition. Com...
|
|
WO/2021/064250A2 |
An isolated or recombinant polypeptide is provided and comprises a sequence selected from the group comprising NI01, α1α2, α2α3, α3α4, α1α2α3, α2 α3 α4, R-NI01, NT-205, H16, H1M NI01-R, 3NH (α1α3α3), H1 (α1α2), H2 (α2α...
|
|
WO/2021/064567A1 |
The present disclosure provides methods of treating cancer in a patient, comprising administering to the patient a chemotherapeutic agent, an immunomodulatory agent, and an antisense compound targeted to STAT3. Also provided herein are c...
|
